Brand name: Auvi-Q
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects - Jorge Máspero, 2017
NICE changes mind and backs new drug for severe asthma | Nursing Times
Advisory Committee Briefing Materials: Available for Public Release
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Reslizumab | Teva UK
Reslizumab | New Drug Approvals
Israeli Pharma gets FDA Approval for Asthma Antibody
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Dosing and Administration
Reslizumab
Australian Public Assessment Report Reslizumab
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Reslizumab Overview - Creative Biolabs
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Clinical Study Protocol Distribution of Eosinophils in Asthma after Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Bli
EU grants marketing authorisation for Teva's asthma drug Cinqaero - Pharmafile
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Medication Detail
Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers - ScienceDirect
Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma | Free directory of clinics in Israel
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
